Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma.
about
Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungsLactam constraints provide insights into the receptor-bound conformation of secretin and stabilize a receptor antagonist.Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma.GABA and Gi/o differentially control circadian rhythms and synchrony in clock neuronsA molecular model for intercellular synchronization in the mammalian circadian clock.Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug designTuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disordersEmerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders.Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeuticsDual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors.The effect of monocyclic and bicyclic analogs of human parathyroid hormone (hPTH)-(1-31)NH2 on bone formation and mechanical strength in ovariectomized rats.A complete substitutional analysis of VIP for better tumor imaging properties.Radiolabeling and in vitro and in vivo characterization of [18F]FB-[R(8,15,21), L17]-VIP as a PET imaging agent for tumor overexpressed VIP receptors.
P2860
Q34999736-37BE3D50-1799-451C-BA0A-22F7D8B34238Q35226241-09EF552C-588C-4E85-ACF3-2ABB82921533Q35295564-58BED764-1891-47B6-AD04-C9981938F67CQ35535797-A68C9004-629C-49E4-AB0D-134590084561Q35539848-25F325CE-187F-493E-A368-E70804A3BB56Q35794588-BB9962DE-943B-47BB-B539-664F344ADBB1Q36460261-DAC9084F-2FB1-47D9-9447-ABA9FCD13CC3Q36830470-B1B52D4B-387A-4412-93EA-3CDE4F8F042DQ36969911-4145DB8F-E17C-41AF-B2E7-28B2377C2B2BQ37191369-388E92DE-1684-409C-9298-DB615CA47B59Q38128288-1559F9AE-C85B-4CF1-8E4F-818363AB9C38Q41121832-01F05701-4A41-4477-A363-1E44C8762247Q43580099-E4E04C5A-3A8C-4F2A-8C17-820955901462Q52955891-9E27A355-A899-485A-B5CF-D280A1C38A6CQ53507768-A17FD4CD-DC13-43F0-B322-D0966C099E83
P2860
Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Design and development of a va ...... rapeutic for bronchial asthma.
@en
type
label
Design and development of a va ...... rapeutic for bronchial asthma.
@en
prefLabel
Design and development of a va ...... rapeutic for bronchial asthma.
@en
P2093
P2860
P356
P1433
P1476
Design and development of a va ...... rapeutic for bronchial asthma.
@en
P2093
Michalewsky J
O'Donnell M
Wasserman MA
P2860
P356
10.1002/BIP.360370203
P577
1995-01-01T00:00:00Z